Table 5.
Side-effects reported among the participant consumed placebo and intervention treatment.
| Author | Year | Intervention/Control | Type of Adverse Event (AE) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea | Eructation/breath odour | Dyspepsia | Fatigue | Headache | Diarrhoea | Gastritis | Oral discomfort | Naso-pharyngitis | |||
| Woelk & Schlafke35 | 2009 | 80 mg/d Silexan | 4 (10.0%) | 3 (7.5%) | 2 (5.0%) | — | — | — | — | — | — |
| 0.5 mg/d Lorazepam | 1 (2.7%) | — | — | 6 (16.2%) | — | — | — | — | — | ||
| Kasper et al.38 | 2015 | 80 mg/d Silexan | — | 6 (7.0%) | — | — | — | 1 (1.2%) | 1 (1.2%) | 1 (1.2%) | — |
| Placebo | — | 0 | — | — | — | — | — | — | — | ||
| Kasper et al.39 | 2016 | 80 mg/d Silexan | 6 (3.8%) | 32 (20.0%) | — | — | 5 (3.1%) | 3 (1.9%) | — | — | 3 (1.9%) |
| Placebo | 2 (1.3%) | 0 | — | — | 11 (7.1%) | 7 (4.5%) | — | — | 8 (5.1%) | ||
| Kasper et al.36 | 2010 | 80 mg/d Silexan | — | — | — | — | — | — | — | — | — |
| Placebo | — | — | — | — | — | — | — | — | — | ||